22157.jpg
2021 U.S. Parkinson's Disease Epidemiology Report: 10-year Forecasts of Parkinson's Disease Epidemiology
August 23, 2021 04:18 ET | Research and Markets
Dublin, Aug. 23, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - US Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The report delivers an...
Dermira_Logo_RGB_R4V2_M01.jpg
Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
June 26, 2017 07:30 ET | Dermira, Inc.
MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations
June 06, 2017 07:30 ET | Dermira, Inc.
MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira to Present at Jefferies 2017 Global Healthcare Conference
May 30, 2017 16:05 ET | Dermira, Inc.
MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
May 16, 2017 16:01 ET | Dermira, Inc.
MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
May 10, 2017 21:32 ET | Dermira, Inc.
MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
May 09, 2017 16:01 ET | Dermira, Inc.
MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update 
May 08, 2017 16:08 ET | Dermira, Inc.
-Submissions for CIMZIA® (certolizumab pegol) and glycopyrronium tosylate remain on schedule for later this year MENLO PARK, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira to Present at Needham 16th Annual Healthcare Conference
March 28, 2017 16:05 ET | Dermira, Inc.
MENLO PARK, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
March 21, 2017 07:30 ET | Dermira, Inc.
MENLO PARK, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...